Taysha Gene Therapies, Inc.
TSHA · XNASCIK 1806310fmd_1RJCBQZ0DND92J7J7G3TCGWS8MManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | 3 | 15 | 8 | 10 |
| Research and development | 32 | 132 | 91 | 57 | 66 | 86 |
| Total operating expenses | 43 | 173 | 165 | 88 | 100 | 120 |
| Compensation and benefits | – | – | – | 27 | 36 | 48 |
| Operating income | (43) | (173) | (162) | (72) | (91) | (110) |
| Interest expense | 0 | 1 | 4 | 5 | 0 | 0 |
| Interest and investment income | – | – | – | 4 | 7 | 9 |
| Other non-operating income (expense) | (17) | (1) | (4) | (39) | 2 | 2 |
| Income tax expense | 0 | – | 0 | 0 | 0 | 0 |
| Net income | (60) | (175) | (166) | (112) | (89) | (109) |
| Net income to common shareholders | (60) | (175) | (166) | (112) | (89) | (109) |